Abeona Therapeutics Inc EV/EBIT
What is the EV/EBIT of Abeona Therapeutics Inc?
The EV/EBIT of Abeona Therapeutics Inc is N/A
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with ev/ebit similar to Abeona Therapeutics Inc
- Walcott Resources has EV/EBIT of N/A
- Oasis Petroleum has EV/EBIT of N/A
- Bionano Genomics Inc has EV/EBIT of N/A
- Voleo Trading Systems Inc has EV/EBIT of N/A
- Fairfax Africa has EV/EBIT of N/A
- Sierra Oncology Inc has EV/EBIT of N/A
- Abeona Therapeutics Inc has EV/EBIT of N/A
- Made.Com Plc Ord Gbp0.000 has EV/EBIT of N/A
- Equity Commonwealth has EV/EBIT of N/A
- Curis Inc has EV/EBIT of N/A
- Emmis Corp has EV/EBIT of N/A
- Nabriva Therapeutics Plc has EV/EBIT of N/A
- International Metals Mining Cor has EV/EBIT of N/A